Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment
about
The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban settingBurden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the communityRetention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisonersChallenges in the Evaluation of Interventions to Improve Engagement Along the HIV Care Continuum in the United States: A Systematic Review.Confronting the HIV, Tuberculosis, Addiction, and Incarceration Syndemic in Southeast Asia: Lessons Learned from MalaysiaResults of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice systemTreatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.Emergency department use by released prisoners with HIV: an observational longitudinal study.An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate.Correlates of HIV infection and being unaware of HIV status among soon-to-be-released Ukrainian prisoners.Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status.Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug usersHIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners.Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.Attitudes toward opioid substitution therapy and pre-incarceration HIV transmission behaviors among HIV-infected prisoners in Malaysia: implications for secondary prevention.Linkage to care for HIV-infected heterosexual men in the United StatesHIV Treatment in the Criminal Justice System: Critical Knowledge and Intervention Gaps.Emergency department use among HIV-infected released jail detainees.Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.Public health implications for adequate transitional care for HIV-infected prisoners: five essential components.HIV-related research in correctional populations: now is the time.Within-prison drug injection among HIV-infected male prisoners in Indonesia: a highly constrained choice.Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study.Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomesSocial and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.Adherence to HIV treatment and care among previously homeless jail detainees.HIV infection and risk of overdose: a systematic review and meta-analysisPatterns of homelessness and implications for HIV health after release from jail.Buprenorphine dose induction in non-opioid-tolerant pre-release prisonersCorrelates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugsAntiretroviral therapy in prevention of HIV and TB: update on current research effortsPredictors of outcome after short-term stabilization with buprenorphinePost-release substance abuse outcomes among HIV-infected jail detainees: results from a multisite study.Frequent emergency department use among released prisoners with human immunodeficiency virus: characterization including a novel multimorbidity index.A cross-national analysis of the effects of methadone maintenance and needle and syringe program implementation on incidence rates of HIV in Europe from 1995 to 2011.Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in MalaysiaIn Their Own Voices: Breaking the Vicious Cycle of Addiction, Treatment and Criminal Justice Among People who Inject Drugs in Ukraine.Latent tuberculosis infection: screening and treatment in an urban setting.
P2860
Q21559628-8A1F0EBE-C742-4244-B573-7F87DFFCD4FCQ28488313-51D8D84A-DA41-4D29-8AAC-C1D8B97CA45BQ28729018-C3163A12-2C27-4263-9FE4-F4F742F8CFFCQ30238794-1AEEE8D9-A64B-457E-9B81-B50419FE0E34Q30250218-C3D6F852-738B-466B-BCDB-E831DFD2F5BEQ30423352-9E65EDE2-CA45-4D42-A766-B47B351F7EF7Q30751889-7747F27F-296B-4E21-BCF6-FFF712847AABQ31083101-581BD296-52BE-40C8-9968-0F808D25E93EQ33702350-68D5E0D8-5CC1-4200-BFC7-D97B39D8CFA8Q33819391-5B42D653-CB6F-4FD8-B4A3-2AE4B931492BQ34169506-0DDF22B1-CE83-4BE7-B708-1F780185A427Q34425700-DA11E511-62DD-44F2-893C-F200D90D95A2Q34754918-2F3A0CD3-0D4F-41C1-9E2D-C01C38902C6CQ34758927-153E92A4-7D8D-4C6C-B27D-0459D64F562DQ34817072-6C3D2693-6A0B-480C-AE05-29346E281723Q34890135-BD8D0FD0-612D-458E-B769-9E9F9D405667Q35019900-E5A18D5C-DCF0-49C6-9367-B0991687E13FQ35109969-56B132E1-6E6B-46F9-9AF6-89A1196C776FQ35112855-BB585D54-A356-47E7-97E4-43DC2C45C2C5Q35160035-807DD7CD-634E-46E9-A47F-367CC52B7EDBQ35164557-BE427FA4-526F-4940-BB2A-30F71324805AQ35528959-3F9808BF-195C-4C3E-9015-1572760188D3Q35557400-C8A3A601-3BDA-4539-AF55-2B5D62644E1AQ35610989-0432C80E-AEF4-4D0A-BAFE-AC28E058C79EQ35712988-DD86256C-50E6-44CA-AFBE-746D358EAE61Q35823204-3C392FC1-773B-47BB-B4F5-0751A4B51382Q35885979-A247624C-CCA5-4B11-A773-6322ED4DB84BQ35898498-6B31F951-C59F-40B5-AA61-C7DAD62F319EQ36223839-BB701127-7B4F-4E0D-B836-BA6CCBE8FE9DQ36248890-5D37D4C2-B9C3-4B64-91C5-B50641D3F69FQ36362007-599817D8-DF9B-46E6-AE23-6A9BB2D22445Q36390767-14613CD0-D20F-4FEA-8C19-2136B341874EQ36493044-B783B984-5243-4914-ABF6-FE99A6AC1587Q36532956-7E71D0C0-E221-46DD-8582-C2B50D3E67BEQ36691614-D148DBF4-77AF-4213-888C-6BA533578FD0Q36758811-92DE4AA0-64AC-4B89-8DE0-09CBF0BA18CCQ36984579-5F0DB574-E632-4E72-A392-31EDC81DE480Q37033936-3602DA06-0822-4F62-8989-CDB4F8CABC75Q37117229-72FB340E-9782-466B-89AD-77DE65188CFDQ37193747-0AAADCC1-B720-4B18-BA20-FBDE340C5737
P2860
Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Improved HIV and substance abu ...... act of buprenorphine treatment
@ast
Improved HIV and substance abu ...... act of buprenorphine treatment
@en
type
label
Improved HIV and substance abu ...... act of buprenorphine treatment
@ast
Improved HIV and substance abu ...... act of buprenorphine treatment
@en
prefLabel
Improved HIV and substance abu ...... act of buprenorphine treatment
@ast
Improved HIV and substance abu ...... act of buprenorphine treatment
@en
P2860
P921
P1476
Improved HIV and substance abu ...... act of buprenorphine treatment
@en
P2093
Frederick L Altice
P2860
P2888
P304
P356
10.1007/S11524-010-9438-4
P577
2010-07-01T00:00:00Z